Concepedia

Wilson Guzman

WG

Statistics

Publications

6

Citations

343

H-Index

6

Active since

2014

Affiliations

Xilio Therapeutics (United States)(Current)

Wilson Guzman is an author at Xilio Therapeutics (United States) specializing in immunotherapy, immune regulation, and tumor immunity.

ORCID

Top concepts

Publications per year

2014–2023

6

Publications

6

The immunocytokine NHS-IL12 as a potential cancer therapeutic

Jonathan K. Fallon, Robert M. Tighe, Giorgio Kradjian et al. · Oncotarget · 2014 · 154 citations · Full text

Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models

Chunxiao Xu, Yanping Zhang, Alex Rolfe et al. · Clinical Cancer Research · 2017 · 74 citations

Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity

Uğur Eskiocak, Wilson Guzman, Benjamin Wolf et al. · JCI Insight · 2020 · 45 citations · Full text

, , +21

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Jennifer Watkins-Yoon, Wilson Guzman, Amanda Oliphant et al. · Blood · 2019 · 39 citations

Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.

Jennifer O’Neil, Wilson Guzman, Oleg Yerov et al. · Journal of Clinical Oncology · 2021 · 16 citations

, , +20

1–5 of 6